Safety And Efficacy Of Bosutinib

DRUG USE INVESTIGATION OF BOSUTINIB FOR CML (POST MARKETING COMMITMENT PLAN)

The objective of this surveillance is to collect information about

1. adverse drug reaction not expected from the LPD (unknown adverse drug reaction)
2. the incidence of adverse drug reactions in this surveillance
3. factors considered to affect the safety and/or efficacy of this drug.

The patients should be registered by central registration system.

Inclusion Criteria:

• Chronic myelogenous leukemia patients resistant or intolerant to prior treatment there is no experience with this drug
• Newly-diagnosed chronic phase Chronic myelogenous leukemia patients there is no experience with this drug

Exclusion Criteria:

• Patients with a history of hypersensitivity
• Women who may possibly be pregnant or become pregnant